#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Acute myeloid leukaemia Neoplasm malignant Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Ovarian cancer Colorectal cancer Hepatocellular carcinoma Dermatitis atopic Dementia Alzheimer's type Asthma Breast cancer metastatic Type 2 diabetes mellitus Non-small cell lung cancer metastatic More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Dementia Thymic carcinoma Hypergammaglobulinaemia benign monoclonal Hyperchylomicronaemia Chronic myelomonocytic leukaemia Autoimmune hepatitis Systemic sclerosis pulmonary Scedosporium infection Idiopathic intracranial hypertension Glycogen storage disease type V Choroidal dystrophy Neuroendocrine carcinoma metastatic Erdheim-Chester disease Non-Hodgkin's lymphoma Vascular malformation More trials…

    Learn about Rare Diseases

    Leiomyosarcoma – Life with Disease Alexander disease Tuberous sclerosis complex Lymphatic malformation – Trials in Disease Mast cell activation syndrome – Life with Disease Hairy cell leukaemia recurrent – Diagnostics Inclusion body myositis – Basic Information Leiomyosarcoma recurrent – Diagnostics Hereditary motor and sensory neuropathy – Trials in Disease Hairy cell leukaemia More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Bisacodyl Immunoglobulin A Flucloxacillin Anb032 Mbs2320 68Ga-Nota-Abscint-Her2 Gozetotide Rtp-026 Sodium Heterodimeric Interleukin-15 Irbesartan Ketamine Hydrochloride R3R01 Utreloxastat OMECAMTIV MECARBIL SURVODUTIDE Mometasone Salmeterol Xinafoate Vismodegib PETHIDINE HYDROCHLORIDE Ivosidenib More therapies…

    Learn about Your Condition

    Pituitary tumour benign Myocardial infarction Adrenogenital syndrome Craniotomy Pouchitis Mucopolysaccharidosis III Gallbladder cancer Myxoid liposarcoma Endocrine disorder Anogenital dysplasia Burning mouth syndrome Lichen planus Deafness Adenocarcinoma gastric Substance use disorder More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden
  1. Clinicaltrials.eu/
  2. Pauls Stradins Clinical University Hospital

Pauls Stradins Clinical University Hospital

Pilsonu Iela 13, Riga, 1002, Latvia

Want to learn more about this study or check if you can participate? Contact us.

  • Study on Long-Term Safety of Tolebrutinib and Teriflunomide for Patients with Multiple Sclerosis

    Recruiting

    3 1 1
    Investigated Diseases:
    • Progressive relapsing multiple sclerosis
    • Relapsing multiple sclerosis
    • Secondary progressive multiple sclerosis
    Investigated Drugs:
    • Anhydrous Cholestyramine
    • Magnetic Resonance Imaging Contrast Media
    • Teriflunomide
    Austria Belgium Bulgaria Croatia Czechia Denmark +17

  • Study on the Effects of MORF-057 for Adults with Moderate to Severe Crohn’s Disease

    Recruiting

    2 1
    Investigated Drugs:
    • Morf-057
    Austria Bulgaria Croatia Czechia Estonia France +8

  • Study on the Long-Term Effects and Safety of Mirikizumab for Patients with Crohn’s Disease

    Recruiting

    3 1 1
    Investigated Drugs:
    • Mirikizumab
    Austria Belgium Croatia Czechia France Germany +8

  • Study on the Effects of Finerenone in Patients with Heart Failure and Preserved Ejection Fraction Hospitalized for Acute Decompensated Heart Failure

    Recruiting

    3 1
    Investigated Drugs:
    • Finerenone
    Austria Bulgaria Croatia Czechia Germany Greece +9

  • Study on the Long-term Safety and Tolerability of Azetukalner for Patients with Epilepsy, Including Focal-onset and Primary Generalized Tonic-Clonic Seizures

    Recruiting

    3 1 1
    Investigated Drugs:
    • Azetukalner
    Austria Belgium Bulgaria Croatia Czechia Finland +10

  • Study on Clazakizumab for Heart Disease in Adults with End-Stage Kidney Disease on Dialysis

    Recruiting

    4 1
    Investigated Drugs:
    • Clazakizumab
    Austria Belgium Bulgaria Croatia Czechia Denmark +16

  • Study on the Effectiveness of Abelacimab for High-Risk Atrial Fibrillation Patients Unsuitable for Oral Anticoagulation

    Recruiting

    3 1
    Investigated Diseases:
    • Atrial fibrillation
    Investigated Drugs:
    • Abelacimab
    Bulgaria Croatia Czechia Estonia Finland Germany +9

  • Study of Lutikizumab, ABBV-382, and Risankizumab for Adults with Moderate to Severe Crohn’s Disease

    Recruiting

    2 1 1
    Investigated Drugs:
    • ABBV-8736
    • Humanised Igg1 Kappa Monoclonal Antibody Against Alfa4Beta7 Integrin
    • Lutikizumab
    Austria Belgium Bulgaria Croatia Czechia Denmark +17

  • Study on Selatogrel for Preventing Heart Attack in Patients with Recent Heart Attack History

    Recruiting

    3 1
    Investigated Diseases:
    • Acute myocardial infarction
    Investigated Drugs:
    • Selatogrel
    Austria Belgium Bulgaria Croatia Czechia Denmark +17

  • Safety and Efficacy of Two Doses of OCUL101 Compared with Aflibercept in Patients with Neovascular Age‑Related Macular Degeneration

    Not yet recruiting

    4 1 1 1
    Investigated Drugs:
    • Aflibercept
    Czechia Hungary Latvia Poland
Previous Page
1 2 3 4 5 6 … 15
Next Page

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!